Recruitment status changed
Before: Active not recruiting. After: Terminated.
Among the trials TrialRedline tracks, 85 changed their ClinicalTrials.gov record in February 2026: 10 status changes to terminated, withdrawn or suspended, 22 primary outcome text edits, 28 completion dates moved later, 3 completion dates moved earlier, 32 enrollment changes, 35 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.
10 in February 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.
Before: Active not recruiting. After: Terminated.
Before: Completed. After: Terminated.
Before: Completed. After: Terminated.
Before: Suspended. After: Terminated.
Before: Enrolling by invitation. After: Terminated.
Before: Recruiting. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Recruiting. After: Suspended.
22 in February 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 versus placebo on frequency of corneal. abrasion symptoms.. After: Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 on frequency of corneal abrasion symptoms..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: In the Randomized Phase, to evaluate the preliminary efficacy and tolerability of multiple regimens of XL184 Measure: In the Expansion Phase, to evaluate the efficacy of XL184 treatment. After: Measure: Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Measure: Expansion Phase: Objective Response Rate (ORR).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Measure: Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events Measure: Safety and Tolerability as Measured by the Number of Cases of Abnormal Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms. Measure: To Evaluate the Long-term Safety and Tolerability of AL002 by Assessing Suicidality Using the Columbia-Suicide Severity Rating Scale (C-SSRS) Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-E Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H. After: Measure: Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Measure: Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events Measure: Safety and Tolerability as Measured by the Number of Cases of Abnormal Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms. Measure: To Evaluate the Long-term Safety and Tolerability of AL002, by Assessing the Number of Suicidal Risk Events Using the Columbia-Suicide Severity Rating Scale (C-SSRS) Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-E by Assessing the Number of Participants With ARIA-E Events Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H by Assessing the Number of Participants With ARIA-H Events.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: The incidence and characteristics of adverse events. After: Measure: Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24. After: Measure: Percent Change From Baseline at Week 24 in Fasting TG.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Increase in Brain Oxygen Tension levels in severe traumatic head injury patients with GCS score of 3-9. After: Measure: Brain Dialysate Concentration Data.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in performance on the Cogstate Cognition battery. After: Measure: Change from Baseline in performance on the Cogstate Cognition battery.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Biodistribution of aglatimagene besadenovec Measure: Biomarkers of immune activation and tumor burden Measure: Biomarkers of immune activation and tumor burden Measure: Biomarkers of immune activation and tumor burden. After: Measure: Biodistribution of aglatimagene besadenovec.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Clinical Safety measured by number of adverse events (AEs ). After: Measure: Clinical Safety.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate adverse events reported by subjects. After: Measure: Phase 1/2: Incidence and severity of adverse events (AEs) Measure: Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids Measure: Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Progression-Free Survival (PFS) by blinded independent central review (BICR) of IDE196 + Crizotinib compared to investigator's choice of treatment Measure: Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment. After: Measure: Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: Measure: Phase 2 Progression-Free Survival (PFS) Measure: Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit. After: Measure: Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (Micro-ITT) Population.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity. After: Measure: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Measure: Percentage of Participants With Clinically Meaningful Changes in Clinical Laboratory Assessments Measure: Percentage of Participants With Clinically Meaningful Changes in Vital Signs Measure: Percentage of Participants With Clinically Meaningful Changes in Electrocardiograms (ECGs) Parameters Measure: Percentage of Participants Who Received At Least One Concomitant Medication.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of subjects achieving Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) score of 0 (clear) or 1 (almost clear). After: Measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Efficacy Outcome: IOP changes from Baseline. After: Measure: IOP Changes From Baseline in the Study Eye.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Maximum Serum Insulin Aspart Concentration, CIAmax Measure: Area Under the Curve (AUC) of Insulin Aspart Serum Concentration from time 0 to 12 hours post-dose, AUCIA(0-12h) Measure: Maximum Serum Human Insulin Concentration, CHImax Measure: Area Under the Curve (AUC) of Human Insulin Serum Concentration from time 0 to 12 hours post-dose, AUCHI(0-12h) Measure: Maximum Glucose Infusion Rate, Gmax Measure: Area Under the Curve (AUC) for Glucose Infusion Rate from time 0 to 12 hours post-dose, AUCG(0-12h). After: Measure: Maximum Serum Insulin Aspart Concentration, CIAmax Measure: Area Under the Curve (AUC) of Insulin Aspart Serum Concentration From Time 0 to 12 Hours Post-dose, AUCIA(0-12h) Measure: Maximum Glucose Infusion Rate, Gmax Measure: Area Under the Curve (AUC) for Glucose Infusion Rate From Time 0 to 12 Hours Post-dose, AUCG(0-12h).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Objective response rate as determined by an Independent Review Committee (IRC). After: Measure: Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate the safety and tolerability of REC-4881 Measure: To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR). After: Measure: Number of Participants with Dose Limiting Toxicities Measure: Objective Response Rate.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety of multiple doses of STK-001. After: Measure: Safety of multiple doses of zorevunersen.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Area under the curve (AUC) from 0 to Week 24 of Ublituximab. After: Measure: Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Part A: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab. After: Measure: Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in peak oxygen uptake (pVO2) by cardiopulmonary exercise testing (CPET). After: Measure: Change From Baseline in pVO2 at Week 24.
28 in February 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.
Before: 1 Feb 2030. After: 31 May 2032.
Before: 1 Sep 2026. After: 1 Dec 2027.
Before: 31 Dec 2025. After: 31 Dec 2026.
Before: 30 Sep 2026. After: 13 Mar 2027.
Before: 8 Feb 2024. After: 12 Jul 2024.
Before: 30 Apr 2026. After: 30 Jun 2026.
Before: 15 Jan 2027. After: 4 Feb 2027.
Before: Mar 2026. After: Dec 2026.
Before: Jun 2027. After: May 2029.
Before: Jan 2008. After: Mar 2008.
Before: Jun 2026. After: Aug 2026.
Before: Oct 2024. After: Nov 2026.
Before: Sep 2024. After: Nov 2026.
Before: Dec 2025. After: Dec 2026.
Before: Jun 2026. After: Aug 2026.
Before: Jan 2027. After: Jun 2027.
Before: Oct 2027. After: Mar 2028.
Before: Dec 2026. After: May 2027.
Before: Dec 2025. After: Jun 2028.
Before: Dec 2026. After: May 2027.
Before: Sep 2026. After: Nov 2026.
Before: Apr 2026. After: Jun 2027.
Before: Jan 2026. After: Apr 2026.
Before: Jun 2026. After: Dec 2026.
Before: Oct 2026. After: Nov 2026.
Showing 25 of 28. Browse all tracked trials to open the rest.
3 in February 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.
Before: 1 Feb 2024. After: 25 Apr 2023.
Before: 26 Sep 2028. After: 28 Apr 2028.
Before: 1 Dec 2026. After: 13 Aug 2026.
32 in February 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.
Before: 915 participants (planned). After: 976 participants (actual).
Before: 80 participants (planned). After: 93 participants (actual).
Before: 16 participants (planned). After: 20 participants (planned).
Before: 470 participants (planned). After: 78 participants (actual).
Before: 915 participants (planned). After: 963 participants (actual).
Before: 8 participants (planned). After: 3 participants (actual).
Before: 80 participants (planned). After: 90 participants (actual).
Before: 350 participants (planned). After: 353 participants (actual).
Before: 1050 participants (planned). After: 1100 participants (actual).
Before: 90 participants (planned). After: 67 participants (actual).
Before: 1050 participants (planned). After: 1121 participants (actual).
Before: 60 participants (planned). After: 13 participants (actual).
Before: 30 participants (planned). After: 45 participants (planned).
Before: 20 participants (actual). After: 35 participants (actual).
Before: 24 participants (actual). After: 21 participants (actual).
Before: 24 participants (planned). After: 74 participants (planned).
Before: 1690 participants (actual). After: 2648 participants (actual).
Before: 400 participants (planned). After: 480 participants (planned).
Before: 20 participants (planned). After: 18 participants (actual).
Before: 180 participants (planned). After: 225 participants (planned).
Before: 118 participants (planned). After: 58 participants (planned).
Before: 40 participants (planned). After: 4 participants (actual).
Before: 40 participants (planned). After: 9 participants (actual).
Before: 120 participants (planned). After: 131 participants (actual).
Before: 400 participants (planned). After: 296 participants (actual).
Showing 25 of 32. Browse all tracked trials to open the rest.
35 in February 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Completed.
Before: Recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Enrolling by invitation. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Showing 25 of 35. Browse all tracked trials to open the rest.
TrialRedline, “Clinical trial registry changes: February 2026”. https://trialredline.com/reports/2026-02
Based on public ClinicalTrials.gov record history. How we collect and check the data